SpringWorks Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• SpringWorks Therapeutics Inc SWTX.OQ reported a quarterly adjusted loss of $1.11​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.18. The mean expectation of seven analysts for the quarter was for a loss of 80 cents per share. Wall Street expected results to range from -93 cents to -62 cents per share.

• Revenue rose 133.7% to $49.09 million from a year ago; analysts expected $66.25 million.

• SpringWorks Therapeutics Inc's reported EPS for the quarter was a loss of $1.11​.

• The company reported a quarterly loss of $83.19 million.

• SpringWorks Therapeutics Inc shares had risen by 4.7% this quarter and gained 27.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 18.4% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "hold"

• Wall Street's median 12-month price target for SpringWorks Therapeutics Inc is $47.00

This summary was machine generated from LSEG data May 9 at 09:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)